Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Europe fights to avoid being sidelined by Trump's world-shaping plans
25/10/2025
Radhakishan Damani bets on market leadership : 5 things going solid for Lenskart IPO
25/10/2025
Where Trump is headed in Asia, and what each country wants from him
25/10/2025
US, China seek to avoid trade war escalation, salvage Trump-Xi meeting in Malaysia talks
25/10/2025
Former IndusInd Bank deputy pays 50% of alleged insider trading gains to Sebi
24/10/2025
Sebi allows transfer of PMS business to simplify operations, ease compliance burden
24/10/2025
